Hansen, Christian Stevns http://orcid.org/0000-0002-5782-3476
Lundby-Christiansen, Louise
Tarnow, Lise
Gluud, Christian
Hedetoft, Christoffer
Thorsteinsson, Birger
Hemmingsen, Bianca
Wiinberg, Niels
Sneppen, Simone B.
Lund, Søren S.
Krarup, Thure
Madsbad, Sten
Almdal, Thomas
Carstensen, Bendix
Jørgensen, Marit E.
Almdal, T.
Boesgaard, T. W.
Breum, L.
Gade-Rasmussen, B.
Duun, E.
Gluud, C.
Hedetoft, C.
Hemmingsen, B.
Jensen, T.
Krarup, T.
Lundby-Christensen, L.
Lund, S.
Madsbad, S.
Mathiesen, E. R.
Pedersen, O.
Perrild, H.
Røder, M.
Sneppen, S. B.
Snorgaard, O.
Tarnow, L.
Thorsteinsson, B.
Vestergaard, H.
Vaag, A.
Wiinberg, N.
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial
https://doi.org/10.1136/bmjopen-2015-008377
Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial
https://doi.org/10.1186/s12933-020-01131-3
Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus—the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial
https://doi.org/10.1136/bmjopen-2015-008376
Funding for this research was provided by:
Novo Nordisk Fonden
Article History
Received: 11 March 2020
Accepted: 18 September 2020
First Online: 26 September 2020
Ethical approval and consent to participate
: The protocol was approved by the Regional Committee on Biomedical Research Ethics (H–D-2007-112), the Danish Medicines Agency and registered with ClinicalTrials.gov (NCT00657943). All participants gave informed consent to participate in the trial. The trial was conducted in accordance to the Helsinki Declaration.
: Not applicable.
: LLC, TA, LT, SSL owns shares in Novo Nordisk A/S: SSL owns shares in in dynamically traded investment funds, which may own stocks from pharmaceutical companies. SSL has reported former employment at Steno Diabetes Center, which is a diabetes hospital and academic institution previously owned by Novo Nordisk. SSL is now employed at Boehringer Ingelheim International GmbH, Ingelheim, Germany. SSL’s contribution was his alone and does not necessarily reflect the official position of Boehringer Ingelheim.